Unlock the secrets to extending survival in metastatic NSCLC: This study reveals how biomarker testing and targeted therapies are transforming patient outcomes in the real world.

Biomarker testing guides selection of targeted therapies in non–small cell lung cancer (NSCLC). Despite its clinical importance, the extent of provider variation in biomarker testing practices and its correlation with patient outcomes has not been thoroughly explored.

Clinical trials are designed to evaluate the safety and efficacy of new therapies or medical devices. During these trials, evidence is gathered to determine if the asset is safe for patients, providing the intended benefit at the appropriate dosage, as well as identifying and minimizing any potential side effects.

In pharmaceutical development, where most therapies never reach the market, early and strategic data investments can make all the difference.

We’re excited to share an important milestone at PurpleLab: we’ve officially submitted our first-ever response to a federal Request for Comment (RFC), and it’s now live on regulations.gov. Ann Phillips, our Senior Director of Regulatory and Standards, pulled together an impressive response to the FDA’s RFC focused on the use of HL7 FHIR (Fast Healthcare…

Healthcare is evolving. We used to focus purely on addressing specific symptoms and treating specific diseases. Our understanding of medicine and medical care was shaped by biology and what goes on inside the body.  But we now know that our health outcomes are also significantly shaped by external factors – everything from our ZIP code…

Generic drugs don’t usually grab headlines. They’re dependable, low-cost and mostly stay in the background. But behind that generic label is a global system that’s far more fragile, and far more important, than it seems. Today, that system is under serious pressure. The United States is facing everything from supply chain disruptions and political instability…

Using non-small cell lung cancer (NSCLC) as an example, PurpleLab and Genentech will explore how to leverage RWD to eliminate blind spots in the patient journey.

Real-world data in life sciences is doing what once seemed impossible: challenging the dominance of traditional clinical trials. For decades, clinical trials have been the gold standard in life sciences research. And it makes sense: they’re rigorously controlled and designed to ensure that the true effects of drugs are being measured. But the real world…